SCHEMBL6903338

SCHEMBL6903338

O=C1c2ccccc2S(=O)(=O)N1c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.58
LMNA P02545 1/20 0.58
CA9 Q16790 9/20 0.56
CA2 P00918 4/20 0.56
ELANE P08246 3/20 0.55
CTSG P08311 1/20 0.55
CEL P19835 1/20 0.55
CA12 O43570 10/20 0.53
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD5 P21918 1/20 0.47
DRD3 P35462 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30367636 1.00 HPGD (0.58) HPGDLMNACA9CA2ELANE
Hydrogen Sulfide SCHEMBL29165723 0.98 HPGD (0.57) HPGDLMNACA9CA2ELANE
SCHEMBL11094946 0.86 CA12 (0.57) HPGDLMNACA9CA2ELANE
SCHEMBL6789680 0.82 CA12 (0.54) HPGDLMNACA9CA2ELANE
SCHEMBL29019945 0.81 CA9 (0.44) HPGDLMNACA9CA2ELANE
SCHEMBL27582170 0.81 HPGD (0.44) HPGDLMNACA9CA2ELANE
SCHEMBL6788104 0.80 NPC1 (0.53) HPGDLMNACA9CA2ELANE
SCHEMBL21933495 0.79 LMNA (0.49) HPGDLMNACA9CA2ELANE
SCHEMBL28096156 0.79 HPGD (0.43) HPGDLMNACA9CA2ELANE
SCHEMBL24205860 0.78 CYP1A2 (0.44) HPGDLMNACA9CA2ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1274781-B1 POLYCARBONATE COMPOSITION RESISTANT TO GAMMA RADIATION BAYER AG (US) 2004-12-15 EP claimed
US-6197854-B1 Polycarbonate composition resistant to gamma radiation BAYER CORPORATION 2001-03-06 US claimed
EP-0742260-B1 (Co)polycarbonates stabilized against gamma-rays BAYER AG (DE) 2000-07-05 EP claimed
US-5684062-A MOLDING MATERIALS WITH STABILIZATION TO RADIATION BAYER AG (DE) 1997-11-04 US claimed
US-20250188046-A1 ULTRAFAST FLOW SYNTHESIS OF FUNCTIONALIZED SULFONYL FLUORIDES AND SUBSEQUENT SUFEX CONNECTIONS VIA LITHIATED CHEMISTRY POSTECH Research and Business Development Foundation (KR) 2025-06-12 US disclosed
CN-106008391-A Preparation method of 2-phenyl-1,1-dioxo-1,2-benzisothiazole-3(2H)-one 东华大学 2016-10-12 CN disclosed
CN-106008391-A Preparation method of 2-phenyl-1,1-dioxo-1,2-benzisothiazole-3(2H)-one 东华大学 2016-10-12 CN disclosed
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase YALE UNIVERSITY (US) 2015-10-01 US disclosed
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase YALE UNIVERSITY (US) 2015-10-01 US disclosed
US-5684062-A MOLDING MATERIALS WITH STABILIZATION TO RADIATION BAYER AG (DE) 1997-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188046-A1 ULTRAFAST FLOW SYNTHESIS OF FUNCTIONALIZED SULFONYL FLUORIDES AND SUBSEQUENT SUFEX CONNECTIONS VIA LITHIATED CHEMISTRY FGFR4, STS, FGFR1 HPGD 4811/4885LMNA 3753/4885CA9 1208/4885
US-20150272939-A1 Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase KDM1B, KDM1A, JMJD1C HPGD 2498/4885LMNA 3900/4885CA9 2616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.